Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gower Publishing

- PMLiVE

Creativity in storytelling: why pharma must invest more in creativity

Chris Ross explores the value, the art and the much-rumoured death of creativity

- PMLiVE

NHS plans to cut certain routine tests as part of cost-saving efforts

Under proposed plans tests will only be used in exceptional situations

- PMLiVE

Y-mAbs files breakthrough neuroblastoma drug in US

Rare cancer type mostly affects babies and young children

- PMLiVE

Diurnal files adrenal insufficiency drug Alkindi in US

Could become only treatment for children with the condition

- PMLiVE

Roche’s Soliris rival satralizumab scores in phase 3 study

Therapy has been filed in US and Europe with decisions expected in 2020

- PMLiVE

Four Health wins Judges Special Recognition Award PMEA 2019

We’re delighted to have won the Judge’s Special Recognition Award at the PMEA Awards 2019! Huge congratulations to the whole team for another amazing win for the GLAD I Took...

Four Agency Worldwide

AstraZeneca AZ

AstraZeneca eyes early 2020 FDA verdict on Imfinzi in SCLC

Will go head-to-head with rival Roche's Tecentriq if approved

- PMLiVE

China updates drug reimbursement list, agrees price cuts

Drugs added include AbbVie's Humira and Roche's Perjeta

- PMLiVE

Pfizer, Flynn face reinstatement of £90m CMA fine

Facing penalty for dramatic price hikes of an epilepsy drug

- PMLiVE

PMEA 2019: Recognising excellence in improving patient outcomes

The 19th annual PMEA programme saw its highest number of entries yet

- PMLiVE

Merck’s Keytruda significantly extends life in some prostate cancer patients

Pivotal study identifies group of 'super responders'

- PMLiVE

Incyte claims FDA priority review for bile duct cancer drug

Significant need for new therapies in hard-to-treat cancer type

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links